GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists
Open accessThe DOI matches its Crossref record; 72 of the 73 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
Type 2 diabetes mellitus (T2DM) represents the main cause of chronic kidney disease (CKD) and end-stage renal disease (ESKD), and diabetic kidney disease (DKD) is a major cause of morbidity and mortality in diabetes. Despite advances in the nephroprotective treatment of T2DM, DKD remains the most common complication, driving the need for renal replacement therapies (RRT) worldwide, and its incidence is increasing. Until recently, prevention of DKD progression was based around strict blood pressure (BP) control, using renin–angiotensin system blockers that simultaneously reduce BP and proteinuria, adequate glycemic control and control of cardiovascular risk factors. Glucagon-like peptide-1 receptor agonists (GLP-1RA) are a new class of anti-hyperglycemic drugs shown to improve cardiovascular and renal events in DKD. In this regard, GLP-1RA offer the potential for adequate glycemic control in multiple stages of DKD without an increased risk of hypoglycemia, preventing the onset of macroalbuminuria and slowing the decline of glomerular filtration rate (GFR) in diabetic patients, also bringing additional benefit in weight reduction, cardiovascular and other kidney outcomes. Results from ongoing trials are pending to assess the impact of GLP-1RA treatments on primary kidney endpoints in DKD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Potential mechanisms for the cardio-nephroprotective effect of GLP-1RA (modified from: Thomas [39] and Greco [40].](https://figures.cochat.ai/paper-figures/c8d9da03e9824ec9909616812b8e0d61/glp-1-receptor-agonists-and-diabetic-kidney-disease-a-call-of-attention-to-figure-1.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Moreover, exendin-4 analogues are resistant to inactivation of dipeptidyl peptidase-4, while GLP-1 analogues are partially metabolized to metabolites, which may be related to the better benefits in cardioprotective effects of liraglutide than exenatide [80, 81].”
The cited source says what the claim attributes to it.
In the citing paper
“However, exendin-4 analogues are metabolized and eliminated by the kidneys.”
In the citing paper
“Their large molecular size or noncovalent attachment to albumin can prevent them from being eliminated by the kidneys.”
In the citing paper
“It was believed that GLP-1 analogues are metabolized in target tissues via the common proteolytic pathway of large proteins.”
In the citing paper
“Moreover, exendin-4 analogues are resistant to inactivation of dipeptidyl peptidase-4, while GLP-1 analogues are partially metabolized to metabolites, which may be related to the better benefits in cardioprotective effects of liraglutide than exenatide [80, 81].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 2×
“(liraglutide) [19,52], SUSTAIN 6 (subcutaneous semaglutide) [20], HARMONY (albiglutide) [53], REWIND (dulaglutide) [37], PIONEER 6 (oral semaglutide) [54] and FREEDOM-CVO (ITCA 650, a novel drug device delivering continuous exenatide) [55] (See Table 2, Figure 2).”
BackgroundSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · cited 13×
“5 or 1 mg of long-acting semaglutide in 3297 T2DM patients at high risk for CV risk, defined by age 50 or older with established cardiovascular disease, chronic heart failure (New York Heart Association class II or III), or CKD stage 3 or higher or age 60 or older with at least one cardiovascular risk factor [20].”
BackgroundInfluentialDapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189 · cited 1×
“73 m2, even when the drug was maintained until the initiation of dialysis [16,18].”
BackgroundEmpagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31149-3 · Cited by 3,163
Foreman, K. J., Marquez, N., Dolgert, A., Fukutaki, K., Fullman, N., McGaughey, M., Pletcher, M. A., Smith, A. E., Tang, K., Yuan, C.-W., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31694-5 · Cited by 2,994
Diabetic Kidney Disease: Challenges, Progress, and Possibilities
Alicic, R. Z., Rooney, M. T., & Tuttle, K. R. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.11491116 · Cited by 2,898 · cited 3×
“Until recently, prevention of DKD progression was based on strict blood pressure (BP) control, using renin–angiotensin system blockers that simultaneously reduce BP and proteinuria, adequate glycemic control and control of cardiovascular risk factors (dyslipidemia, obesity and smoking), as well as nephrotoxic drug avo…”
BackgroundMethodLixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409 · cited 15×
“outcomes in 60,090 T2DM patients: ELIXA (lixisenatide) [50], EXSCEL (exenatide) [51], LEADER”
BackgroundResultInfluentialEffects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes
Holman, R. R., Bethel, M. A., Mentz, R. J., Thompson, V. P., Lokhnygina, Y., Buse, J. B., Chan, J. C., Choi, J., Gustavson, S. M., Iqbal, N., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612917 · Cited by 2,162
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Husain, M., Birkenfeld, A. L., Donsmark, M., Dungan, K., Eliaschewitz, F. G., Franco, D. R., Jeppesen, O. K., Lingvay, I., Mosenzon, O., Pedersen, S. D., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901118 · Cited by 1,997
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868 · cited 3×
“Dulaglutide [28] REWIND 9901 T2D and CVD or CV risk factors 5.”
BackgroundHernandez, A. F., Green, J. B., Janmohamed, S., D'Agostino, R. B., Granger, C. B., Jones, N. P., Leiter, L. A., Rosenberg, A. E., Sigmon, K. N., Somerville, M. C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32261-x · Cited by 1,829
Adler, A. I., Stevens, R. J., Manley, S. E., Bilous, R. W., Cull, C. A., Holman, R. R., & UKPDS Group (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00712.x · Cited by 1,816
Kristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., Køber, L., Petrie, M. C., & McMurray, J. J. V. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30249-9 · Cited by 1,663 · cited 2×
“A recently published systematic review and meta-analysis of cardiovascular outcome trials with GLP-1RA screened 27 publications and seven of the above-mentioned clinical trials [56].”
BackgroundKidney disease and increased mortality risk in type 2 diabetes
Afkarian, M., Sachs, M. C., Kestenbaum, B., Hirsch, I. B., Tuttle, K. R., Himmelfarb, J., & de Boer, I. H. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012070718 · Cited by 1,298
Liraglutide and renal outcomes in type 2 diabetes
Mann, J. F. E., Ørsted, D. D., Brown-Frandsen, K., Marso, S. P., Poulter, N. R., Rasmussen, S., Tornøe, K., Zinman, B., & Buse, J. B. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1616011 · Cited by 1,253
Prevalence of diabetes mellitus and impaired glucose regulation in Spain: the Di@bet.es Study
Soriguer, F., Goday, A., Bosch-Comas, A., Bordiú, E., Calle-Pascual, A., Carmena, R., Casamitjana, R., Castaño, L., Castell, C., Catalá, M., et al. (2012) · Diabetologia · doi:10.1007/s00125-011-2336-9 · Cited by 1,146
Pyke, C., Heller, R. S., Kirk, R. K., Ørskov, C., Reedtz-Runge, S., Kaastrup, P., Hvelplund, A., Bardram, L., Calatayud, D., & Knudsen, L. B. (2014) · Endocrinology · doi:10.1210/en.2013-1934 · Cited by 876 · cited 1×
“GLP-1R have been identified in vascular smooth muscle cells of preglomerular arterioles in human and experimental animal kidneys [61] but cannot be easily detected by immunohistochemistry or imaging, and levels of expression may be below the sensitivity of the techniques [62].”
BackgroundTuttle, K. R., Lakshmanan, M. C., Rayner, B., Busch, R. S., Zimmermann, A. G., Woodward, D. B., & Botros, F. T. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30104-9 · Cited by 648
Nauck, M. A., Meier, J. J., Cavender, M. A., Abd El Aziz, M., & Drucker, D. J. (2017) · Circulation · doi:10.1161/circulationaha.117.028136 · Cited by 582
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s010 · Cited by 471
Glucagon-Like Peptide 1 Induces Natriuresis in Healthy Subjects and in Insulin-Resistant Obese Men
Gutzwiller, J.-P., Tschopp, S., Bock, A., Zehnder, C. E., Huber, A. R., Kreyenbuehl, M., Gutmann, H., Drewe, J., Henzen, C., Goeke, B., et al. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031403 · Cited by 442
GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes
Muskiet, M. H. A., Tonneijck, L., Smits, M. M., van Baar, M. J. B., Kramer, M. H. H., Hoorn, E. J., Joles, J. A., & van Raalte, D. H. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.123 · Cited by 407
Cefalu, W. T., Kaul, S., Gerstein, H. C., Holman, R. R., Zinman, B., Skyler, J. S., Green, J. B., Buse, J. B., Inzucchi, S. E., Leiter, L. A., et al. (2018) · Diabetes Care · doi:10.2337/dci17-0057 · Cited by 363
Mosenzon, O., Blicher, T. M., Rosenlund, S., Eriksson, J. W., Heller, S., Hels, O. H., Pratley, R., Sathyapalan, T., Desouza, C., Abramof, R., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30192-5 · Cited by 351
Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors
Scheen, A. J. (2018) · Circulation Research · doi:10.1161/circresaha.117.311588 · Cited by 286
The DCCT Research Group (1988) · Diabetes · doi:10.2337/diab.37.4.476 · Cited by 262
Muskiet, M. H. A., Tonneijck, L., Huang, Y., Liu, M., Saremi, A., Heerspink, H. J. L., & van Raalte, D. H. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30268-7 · Cited by 259 · cited 1×
“In the ELIXA (Evaluation of Lixisenatide in Acute Coronary Syndrome) trial [50,57], eGFR was <60 mL/min/1.”
BackgroundBailey, R. A., Wang, Y., Zhu, V., & Rupnow, M. F. (2014) · BMC Research Notes · doi:10.1186/1756-0500-7-415 · Cited by 247
Davies, M. J., Bain, S. C., Atkin, S. L., Rossing, P., Scott, D., Shamkhalova, M. S., Bosch-Traberg, H., Syrén, A., & Umpierrez, G. E. (2016) · Diabetes Care · doi:10.2337/dc14-2883 · Cited by 235 · cited 6×
“Semaglutide effected a 36% reduction (HR 0.64 (95% CI 0.46–0.88, p = 0.005)) in a secondary combined kidney endpoint (new-onset macroalbuminuria, doubling serum creatinine reaching an eGFR 45 mL/min/1.73 m2, initiation of renal replacement therapy or renal death).”
BackgroundInfluentialSarafidis, P., Ferro, C. J., Morales, E., Ortiz, A., Malyszko, J., Hojs, R., Khazim, K., Ekart, R., Valdivielso, J., Fouque, D., et al. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfy407 · Cited by 204
Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes
Gautier, J.-F., Choukem, S.-P., & Girard, J. (2008) · Diabetes & Metabolism · doi:10.1016/s1262-3636(08)73397-4 · Cited by 183
Kapitza, C., Nosek, L., Jensen, L., Hartvig, H., Jensen, C. B., & Flint, A. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.443 · Cited by 175
GLP-1 receptor agonists and kidney protection
Greco, E., Russo, G., Giandalia, A., Viazzi, F., Pontremoli, R., & De Cosmo, S. (2019) · Medicina · doi:10.3390/medicina55060233 · Cited by 173
Farrington, K., Covic, A. C., Aucella, F., Clyne, N., de Vos, L., Findlay, A., Fouque, D. P., Grodzicki, T. K., Iyasere, O. U., Jager, K. J., et al. (2016) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfw356 · Cited by 171
Farrington, K., Covic, A. C., Nistor, I., Aucella, F., Clyne, N., Vos, L. D., Findlay, A., Fouque, D. P., Grodzicki, T. K., Iyasere, O. U., et al. (2017) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfw411 · Cited by 171
Documento de consenso para la detección y manejo de la enfermedad renal crónica
Martínez‐Castelao, A., Górriz, J. L., Bover, J., la Morena, J. S.-D., Cebollada, J., Escalada, J., Esmatjes, E., Fácila, L., Gamarra, J., Gràcia, S., et al. (2014) · Atención Primaria · doi:10.1016/j.aprim.2014.09.002 · Cited by 170
Self-citationWang, L., Li, P., Tang, Z., Yan, X., & Feng, B. (2016) · Scientific Reports · doi:10.1038/srep33251 · Cited by 165 · cited 1×
“Treatment with GLP-1RA is able to modulate the microbiome of mice; accordingly, liraglutide could modulate the composition of the gut microbiota, leading to a more lean-related profile that was consistent with its weight-losing effect [65].”
BackgroundThe Glucagon-Like Peptide-1 Receptor—or Not?
Pyke, C., & Knudsen, L. B. (2013) · Endocrinology · doi:10.1210/en.2012-2124 · Cited by 154 · cited 1×
“GLP-1R have been identified in vascular smooth muscle cells of preglomerular arterioles in human and experimental animal kidneys [61] but cannot be easily detected by immunohistochemistry or imaging, and levels of expression may be below the sensitivity of the techniques [62].”
BackgroundPrevalence of chronic kidney disease in patients with type 2 diabetes in Spain: PERCEDIME2 study
Rodríguez‐Poncelas, A., Garre‐Olmo, J., Franch‐Nadal, J., Díez‐Espino, J., Mundet, X., Barrot, J., de Tuero, G. C., & RedGDPS Study Group (2013) · BMC Nephrology · doi:10.1186/1471-2369-14-46 · Cited by 143
Katout, M., Zhu, H., Rutsky, J., Shah, P., Brook, R. D., Zhong, J., & Rajagopalan, S. (2014) · American Journal of Hypertension · doi:10.1093/ajh/hpt196 · Cited by 140
Marbury, T. C., Flint, A., Jacobsen, J. B., Derving Karsbøl, J., & Lasseter, K. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0528-2 · Cited by 130
Tonneijck, L., Smits, M. M., Muskiet, M. H. A., Hoekstra, T., Kramer, M. H. H., Danser, A. H. J., Diamant, M., Joles, J. A., & van Raalte, D. H. (2016) · Diabetologia · doi:10.1007/s00125-016-3938-z · Cited by 126 · cited 1×
“However, this was not replicated in patients with T2DM [69], which was shown/hypothesized to depend on impaired nitric oxide-dependent vasodilation in T2DM patients.”
BackgroundInsulin-associated weight gain in obese type 2 diabetes mellitus patients: What can be done?
Brown, A., Guess, N., Dornhorst, A., Taheri, S., & Frost, G. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13009 · Cited by 113 · cited 2×
“Insulin treatment is associated with an increased risk of hypoglycemia [11], weight gain and increased sodium reabsorption in the proximal tubule [41].”
BackgroundThe potential and pitfalls of GLP-1 receptor agonists for renal protection in type 2 diabetes
Thomas, M. C. (2017) · Diabetes & Metabolism · doi:10.1016/s1262-3636(17)30069-1 · Cited by 111
Effects of GLP-1 in the Kidney
Skov, J. (2014) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-014-9287-7 · Cited by 106
Idorn, T., Knop, F. K., Jørgensen, M. B., Jensen, T., Resuli, M., Hansen, P. M., Christensen, K. B., Holst, J. J., Hornum, M., & Feldt-Rasmussen, B. (2016) · Diabetes Care · doi:10.2337/dc15-1025 · Cited by 96
Short-Term Changes after a Weight Reduction Intervention in Advanced Diabetic Nephropathy
Friedman, A. N., Chambers, M., Kamendulis, L. M., & Temmerman, J. C. (2013) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04010413 · Cited by 93
Incidence of end-stage renal disease following bariatric surgery in the Swedish Obese Subjects Study
Shulman, A., Peltonen, M., Sjöström, C. D., Andersson-Assarsson, J. C., Taube, M., Sjöholm, K., le Roux, C. W., Carlsson, L. M. S., & Svensson, P.-A. (2018) · International Journal of Obesity · doi:10.1038/s41366-018-0045-x · Cited by 86 · cited 1×
“The beneficial impact was more evident in patients with pathological albuminuria [26].”
BackgroundLee, S., & Lee, D. Y. (2017) · Annals of Pediatric Endocrinology & Metabolism · doi:10.6065/apem.2017.22.1.15 · Cited by 79
Thomson, S. C., Kashkouli, A., & Singh, P. (2013) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00064.2012 · Cited by 71
Herzberg-Schäfer, S. A., Heni, M., Stefan, N., Häring, H., & Fritsche, A. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01648.x · Cited by 68
Sloan, L. A. (2019) · Journal of Diabetes · doi:10.1111/1753-0407.12969 · Cited by 58
Renal Outcomes in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL)
Bethel, M. A., Mentz, R. J., Merrill, P., Buse, J. B., Chan, J. C. N., Goodman, S. G., Iqbal, N., Jakubonienė, N., Katona, B. G., Lokhnygina, Y. V., et al. (2018) · Diabetes · doi:10.2337/db18-522-p · Cited by 54
Yin, W., Xu, S., Wang, Z., Liu, H., Peng, L., Fang, Q., Deng, T., Zhang, W., & Lou, J. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.11.076 · Cited by 51
Consensus document for the detection and management of chronic kidney disease.
Martínez-Castelao, A., Górriz, J. L., la Morena, J. S.-D., Cebollada, J., Escalada, J., Esmatjes, E., Fácila, L., Gamarra, J., Gràcia, S., Hernánd-Moreno, J., et al. (2014) · PubMed · doi:10.3265/nefrologia.pre2014.feb.12455 · Cited by 49
Self-citationFernández‐Fernández, B., Fernández-Prado, R., Górriz, J. L., Martínez‐Castelao, A., Navarro‐González, J. F., Porrini, E., Soler, M. J., & Ortíz, A. (2019) · Clinical Kidney Journal · doi:10.1093/ckj/sfz070 · Cited by 48
Self-citationGlycemia Determines the Effect of Type 2 Diabetes Risk Genes on Insulin Secretion
Heni, M., Ketterer, C., Thamer, C., Herzberg-Schäfer, S. A., Guthoff, M., Stefan, N., Machicao, F., Staiger, H., Fritsche, A., & Häring, H.-U. (2010) · Diabetes · doi:10.2337/db10-0674 · Cited by 47
The Effect of Weight Loss in Obesity and Chronic Kidney Disease
Morales, E., & Praga, M. (2012) · Current Hypertension Reports · doi:10.1007/s11906-012-0247-x · Cited by 35
Ramírez, G., Morrison, A. D., & Bittle, P. A. (2013) · Endocrine Practice · doi:10.4158/ep12306.ra · Cited by 35
Treatment of Metabolic Syndrome Slows Progression of Diabetic Nephropathy
Pérez, E. G. D., Almeda‐Valdés, P., Ramos, D. C., Campos-Barrera, E., Muñóz-Hernández, L. L., & Gomez-Perez, F. J. (2011) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2011.0056 · Cited by 34
Nephroprotection by Hypoglycemic Agents: Do We Have Supporting Data?
Górriz, J. L., Nieto, J., Navarro‐González, J. F., Molina, P., Martínez‐Castelao, A., & Pallardó, L. (2015) · Journal of Clinical Medicine · doi:10.3390/jcm4101866 · Cited by 34
Self-citationChoice of endpoint in kidney outcome trials: considerations from the EMPA-REG OUTCOME® trial
Perkovic, V., Koitka-Weber, A., Cooper, M. E., Schernthaner, G., Pfarr, E., Woerle, H. J., von Eynatten, M., & Wanner, C. (2020) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfz179 · Cited by 31
Patient-Reported and Actionable Safety Events in CKD
Ginsberg, J. S., Zhan, M., Diamantidis, C. J., Woods, C. M., Chen, J., & Fink, J. C. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013090921 · Cited by 29
Effects of incretin-based therapies on renal function
Tsimihodimos, V., & Elisaf, M. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.10.049 · Cited by 22
Martínez, J. J. G. (2019) · Hipertensión y Riesgo Vascular · doi:10.1016/j.hipert.2019.03.005 · Cited by 18
Martínez‐Castelao, A., Górriz, J. L., Ortíz, A., & Navarro‐González, J. F. (2017) · Nefrología · doi:10.1016/j.nefro.2017.06.001 · Cited by 9
Self-citationPerkovic, V., Bain, S. C., Bakris, G. L., Buse, J. B., Gondolf, T., Idorn, T., Lausvig, N. L., Mahaffey, K. W., Marso, S. P., Nauck, M. A., et al. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfz106.fp482 · Cited by 8
Martínez‐Castelao, A., Górriz, J. L., Ortíz, A., & Navarro‐González, J. F. (2017) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2017.11.012 · Cited by 6
Self-citationTakayanagi, R., Uchida, T., Kimura, K., & Yamada, Y. (2018) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b17-00237 · Cited by 6
Research works printed but not linked: 1
- 2019, New glucose-lowering drugs for reducing cardiovascular risk in patients with type2 diabetes mellitus, Hipertens. Riesgo Vasc., 36, 145
Cited by
Gupta, S., Dominguez, M., & Golestaneh, L. (2023) · Medical Clinics of North America · doi:10.1016/j.mcna.2023.03.004 · Cited by 337
Yamada, T., Wakabayashi, M., Bhalla, A., Chopra, N., Miyashita, H., Mikami, T., Ueyama, H., Fujisaki, T., Saigusa, Y., Yamaji, T., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01197-z · Cited by 159
Documento de información y consenso para la detección y manejo de la enfermedad renal crónica
Maset, R. G., Bover, J., Segura, J., Diezhandino, M. G., del Hoyo, J. C., Martín, J. E. S., Fácila, L., Gamarra, J., García‐Donaire, J. A., Matarin, L. G., et al. (2021) · Nefrología · doi:10.1016/j.nefro.2021.07.010 · Cited by 206
Self-citationIncretin Hormones and Type 2 Diabetes—Mechanistic Insights and Therapeutic Approaches
Boer, G. A., & Holst, J. J. (2020) · Biology · doi:10.3390/biology9120473 · Cited by 152
Diabetic Nephropathy: Pathogenesis, Mechanisms, and Therapeutic Strategies
Dwivedi, S., & Sikarwar, M. S. (2024) · Hormone and Metabolic Research · doi:10.1055/a-2435-8264 · Cited by 165
Metadata
- Authors
- Górriz, J. L., Soler, M. J., Navarro-González, J. F., García-Carro, C., Puchades, M. J., D’Marco, L., Martínez Castelao, A., Fernández-Fernández, B., Ortiz, A., Górriz-Zambrano, C., Navarro-Pérez, J., & Gorgojo-Martinez, J. J.
- Affiliations
- Universitat de València (ES)
- Universitat Autònoma de Barcelona (ES)
- Unidad de Investigación y Servicio de Nefrología, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Universidad de La Laguna, 38200 Tenerife, Spain
- IIS-Fundación Jimenez Diaz UAM and School of Medicine, Universidad Autonoma de Madrid, 28040 Madrid, Spain
- Nephrology Department, Bellvitge University Hospital, Hospitalet, 08907 Barcelona, Spain
- CAP Sant Pere, ABS Reus 1, 43202 Tarragona, Spain
- Unidad de Endocrinología y Nutrición, Fundación Hospital Alcorcón, 28922 Madrid, Spain
- Corresponding author
- Górriz, José Luis
- ORCID
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2020-03-30
- Volume
- 9
- Issue
- 4
- Pages
- 947
- ISSN
- 2077-0383 (ISSN-L)
- PMC
- PMC7231090
- OpenAlex
- W3014018229
- Cited by
- 144
- References
- 72
- Citations by year
- 2026: 11 · 2025: 18 · 2024: 23 · 2023: 29 · 2022: 38 · 2021: 23 · 2020: 2
- FWCI
- 3.70
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Journal of Clinical Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, cc-by)
- Biblos-e Archivo (Universidad Autónoma de Madrid) (submittedVersion, public-domain)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Hispana (submittedVersion)
- Funders
- Boehringer Ingelheim
- Amgen
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Amicus Therapeutics
- Fresenius Medical Care North America
- Novo Nordisk
- Astellas Pharma
- Servier
- Sanofi Genzyme
- Instituto de Salud Carlos III (RD16/0009, RD16/0009/0022)
- Janssen Pharmaceuticals
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- GLP-1 receptor agonists, diabetic nephropathy, type 2 diabetes, renal protection, glycemic control, macroalbuminuria, glomerular filtration rate decline, renin-angiotensin system inhibitors, proteinuria, weight loss, cardiovascular outcomes, renal replacement therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.